Novavax RSV vaccine performs well in early stage trial

Novavax's (NVAX +1.5%) vaccine for respiratory syncytial virus (RSV), which causes infections of the lungs and breathing passages, performed well in a Phase I trial of 220 healthy adults aged 60 years and older.

The RSV F vaccine was compatible when administered with a flu vaccine, was well-tolerated, and it helped increase antibodies with potentially protective effects. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs